Organization | Misr International University

Misr International University Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2015

NCT05963334

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Christian Blind Mission | Fixed Prosthodontics Department, Misr International University | Misr International University

Active Ingredients

Drugs in Phase 3 Trials (5)

acetylcysteine (mucomyst) (1 trial)

chlorhexidine (hibitane) (2 trials)

cilostazol (pletal) (1 trial)

metformin (glucophage) (1 trial)

moringa oleifera (1 trial)

Drugs in Phase 2 Trials (3)

carboplatin (paraplatin) (1 trial)

l-carnosine (1 trial)

paclitaxel (taxol) (1 trial)

Drugs in Other Trials (3)

pentoxifylline (trental) (1 trial)

ubiquinone (1 trial)

vitamin c (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Dental Plaque (Phase 3)

Peripheral Nervous System Diseases (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 10
# of Trial APIs: 11